HPV4 Vaccine Transitioning to HPV9 Vaccine

The current Ontario supply of HPV4 vaccine expired on March 14, 2019, and will no longer be available for order in Canada, as Merck is transitioning to the HPV9 vaccine (Gardasil®9).

Starting March 15, 2019, publicly funded HPV9 vaccine can be offered to:

1. **Male students in grade 9** (born in 2004) and **female students in grades 9 to 12** (routine vaccine program):
   - a. Who have received at least one dose of the HPV4 vaccine and would like to complete the series; or
   - b. Who have not received any previous doses of the HPV4 vaccine and would like to initiate the series.

2. **Males 9 to 26 years of age** (high-risk vaccine program)

The use of HPV9 vaccine to complete an HPV4 series aligns with recommendations by the National Advisory Committee on Immunization (NACI). However, as there is no interchangeability data currently available for a mixed regimen of HPV vaccines, a substitution notice will be sent with all HPV9 orders, indicating that a mixed series will not provide full protection against the additional five strains in the HPV9 vaccine.

Individuals who wish to be vaccinated with a complete series of HPV9 will need to purchase the additional HPV9 vaccine doses privately.

Individuals who have completed their HPV4 series as of March 14, 2019 will be considered up-to-date with their HPV immunization and will not be eligible for publicly funded HPV9 vaccine.

Students in grades 7 and 8 will continue to initiate/complete their publicly funded HPV9 vaccine series at the Health Department’s school-based immunization clinics.

Health care provider resources now available to order online durham.ca/HCP.